Associated characteristics with relapse-free survival by uni- and multi-variate survival analysis

Characteristics	Univariate analysis			Multivariate analysis
Characteristics	Mean survival (months) (95% CI)	Log rank	P	HR (95% CI)	P
Age (years)		2.034	0.154
= 50	51 (4160)
> 50	61 (5369)
Menstrual status		1.927	0.165
Premenopausal	51 (4260)
Postmenopausal	61 (5370)
Clinical tumor stage		0.001	0.985
cT12	57 (4865)
cT34	53 (4463)
Clinical lymph node stage		2.919	0.088
cN01	66 (5577)			1
cN23	52 (4560)			1.554 (0.5634.291)	0.395
Pathologic tumor stage		0.287	0.592
yT12	58 (5065)
yT34	50 (3863)
Pathologic lymph node stage		0.195	0.658
yN0	60 (4574)
yN13	55 (4862)
Histological grade		9.630	0.008*
12	67 (5975)			1
3	49 (4057)			3.422 (1.1889.858)	0.023*
Unclearly	57 (5757)
Histologic type		1.921	0.166
Invasive ductal carcinoma	56 (4962)
Other	57 (5757)
ER		8.005	0.005*
Negative	42 (3253)			1
Positive	63 (5670)			0.477 (0.1271.792)	0.273
PR		4.765	0.029*
Negative	46 (3755)			1
Positive	63 (5571)			0.795 (0.2083.042)	0.738
Her-2		1.591	0.207
Negative	60 (5267)
Positive	50 (3961)
Postsurgical Ki67		8.526	0.004*
= 25%	65 (5873)			1
> 25%	44 (3553)			1.093 (0.4492.664)	0.844
Ki67 decrease		7.327	0.007*
= 12.5%	46 (3754)			1
> 12.5%	66 (5974)			0.353 (0.1470.850)	0.020*
Molecular subtype		5.875	0.118
HR(+)/Her-2()	62 (5470)
HR(+)/Her-2(+)	62 (4677)
HR()/Her-2(+)	43 (2956)
TN	41 (2358)

*P < 0.05 was considered statistically significant. Abbreviations: ER, estrogen receptor; Her-2, human epidermal growth factor receptor 2; HR(+), hormonal receptor (+); PR, progestrone receptor; TN, triple negative.